ArticleJournal of pharmacy & bioallied sciences2022
Evaluation of Salivary Alkaline Phosphatase and Glutathione Peroxidase Levels in Diabetic and Nondiabetic Participants With and Without Smoking Habits: A Case-Control Study.
Article in Journal of pharmacy & bioallied sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of the current evidence suggests that tobacco smoking increases the risk of diabetes. Salivary alkaline phosphatase (ALP) and glutathione peroxidase (GSHPx) considered a biomarker to detect various oral diseases. Several studies suggest that smoking habits tend to alter ALP and GSHPx levels. However, at present, there is no much information about these enzymes in smokers with diabetes. Hence, the study aimed to evaluate the status of salivary ALP and GSHPx levels in diabetic and nondiabetic participants with and without smoking habits. Materials and Methods: This case-control study was approved by the Institutional Ethical Committee. A total of 60 male participants between the age group 35-50 years were recruited. Informed consent was obtained from participants. Participants were categorized into four groups: Group I - Smokers with diabetes ( Results: Nonsmoker diabetic participants demonstrated significantly higher ALP levels as compared to other groups ( Conclusions: Salivary ALP can be used as a clinical biomarker to be correlated for evaluating diabetes. GSHPx activity can be used to understand the response of supplementation therapy in smokers with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.